

SKYEPHARMA PLC
Form 6-K
March 09, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March , 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

SkyePharma PLC

Edgar Filing: SKYEPHARMA PLC - Form 6-K

Extraordinary General Meeting

LONDON, UK, 9 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces the results of the Meeting held today. The resolution considered by the meeting was the appointment of Mr Robert Th **rejected** by a significant proportion of both votes and number of shareholders.

The resolution to appoint Mr Thian as a director was defeated by a majority of 28.5 million share

For the resolution: 225,843,014 votes (880 shareholders)
Against the resolution: 254,377,799 votes (2984 shareholders)

In terms of votes cast, 53% of votes were against the resolution and 47% were for the re
shareholders voting, 23% voted for the resolution and 77% against.

Dr Jerry Karabelas, SkyePharma's Non-Executive Chairman, said: "The EGM is now behind us. We ca
for the benefit of all shareholders."

For further information please contact:

SkyePharma PLC	+44 207 491 1777
Frank Condella, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	+44 207 491 5124
Sandra Haughton, US Investor Relations	+1 212 753 5780
Buchanan Communications	+44 207 466 5000
Tim Anderson / Mark Court/Rebecca Skye Dietrich	

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te
and more effective drug formulations. There are now eleven approved products incorporating Skye
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi
www.skyepharma.com.

*Certain statements in this news release are forward-looking statements and are made in reliance
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio
statements are reasonable, it can give no assurance that these expectations will materialize. E
risks and uncertainties, actual results may vary significantly from those expressed or impli
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on
cause differences between actual results and those implied by the forward-looking statements c
without limitation, risks related to the development of new products, risks related to obtainin
for existing, new or expanded indications of existing and new products, risks related to SkyePh
on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability
maintain or expand market share in the face of changes in customer requirements, competition an
to regulatory compliance, the risk of product liability claims, risks related to the ownership
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga
forward-looking statement to reflect events or circumstances after the date of this release.*

END

SIGNATURES

Edgar Filing: SKYEPHARMA PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: March 09, 2006